Cargando…

Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications

The efficacy and safety of vitamin K antagonists (VKAs) as oral anticoagulants (OACs) depend on the quality of anticoagulation control, as reflected by the mean time in therapeutic range (TTR). Several factors may be involved in poor TTR such as comorbidities, high inter-individual variability, inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camelo-Castillo, Anny, Rivera-Caravaca, José Miguel, Orenes-Piñero, Esteban, Ramírez-Macías, Inmaculada, Roldán, Vanessa, Lip, Gregory Y. H., Marín, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916955/ https://www.ncbi.nlm.nih.gov/pubmed/33670220 http://dx.doi.org/10.3390/jcm10040715

Ejemplares similares

Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2021)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics
por: Sánchez-Fuentes, Ana, et al.
Publicado: (2022)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2021)

Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS
por: Ding, Wern Yew, et al.
Publicado: (2021)

Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2022)

Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review
por: Violi, Francesco, et al.
Publicado: (2016)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Subgingival microbiota in health compared to periodontitis and the influence of smoking
por: Camelo-Castillo, Anny J., et al.
Publicado: (2015)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial
por: Ding, Wern Yew, et al.
Publicado: (2022)

Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients
por: Heidbuchel, Hein, et al.
Publicado: (2015)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2022)

Edoxaban in the Evolving Scenario of Non Vitamin K Antagonist Oral Anticoagulants Imputed Placebo Analysis and Multiple Treatment Comparisons
por: Verdecchia, Paolo, et al.
Publicado: (2014)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis
por: Wang, Kang-Ling, et al.
Publicado: (2015)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials
por: Domek, Magdalena, et al.
Publicado: (2020)

Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers
por: Peña-Romero, Alicia Cristina, et al.
Publicado: (2022)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS‐BLED and GARFIELD‐AF Bleeding Scores
por: Proietti, Marco, et al.
Publicado: (2018)

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients without previous oral anticoagulants or stable under warfarin: a nationwide cohort study
por: Liu, Shin-Huei, et al.
Publicado: (2023)

Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
por: Pastori, Daniele, et al.
Publicado: (2018)

Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2021)

Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2017)

Long‐Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC‐Stroke and CHA (2) DS (2)‐VASc Scores
por: Rivera‐Caravaca, José Miguel, et al.
Publicado: (2017)

Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2019)

Evidences of SARS-CoV-2 virus air transmission indoors using several untouched surfaces: A pilot study
por: Orenes-Piñero, Esteban, et al.
Publicado: (2021)

Mortality associated with the use of non‐vitamin K antagonist oral anticoagulants in cancer patients: Dabigatran versus rivaroxaban
por: Lin, Yu‐Sheng, et al.
Publicado: (2021)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asians With Nonvalvular Atrial Fibrillation: A Network Meta-Analysis
por: Xiong, Qinmei, et al.
Publicado: (2019)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l35nqsohttqsha3ehvfo6j3hel